Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Samsung Biologics Co., Ltd.
EIR
•Samsung Biologics Co., Ltd.•May 11, 2018

Samsung Biologics Co., Ltd. – FDA EIR, May 11, 2018

Record Details

The U.S. Food and Drug Administration (FDA) conducted a pre-approval inspection of Samsung Biologics Corporation, Ltd.'s facility in Incheon, Korea, from May 07-11, 2018. This inspection was undertaken to assess the site's capability to manufacture a specific drug product, supporting an application to designate Samsung Biologics as an additional production location. The inspection adhered to regulatory guidelines including CP 7356.002M, CP 7346.832, and ICH Q7, focusing on the facility's Quality, Facilities and Equipment, Production, Materials, and Laboratory systems. During the inspection, five significant issues were identified and documented on an FDA Form 483. These primary observations included a failure to consistently follow procedures aimed at preventing microbial contamination in sterile drug products. Furthermore, the Quality Control Unit was found to lack adequate authority to review production records to ensure accuracy and prevent errors. Inspectors also noted instances where deviations from written Good Manufacturing Practice (GMP) procedures were not formally recorded. Other issues encompassed insufficient maintenance of equipment used in production and deficiencies in the environmental monitoring processes within aseptic processing areas. These observations necessitate that the company develop and implement comprehensive corrective actions to ensure full compliance with regulatory requirements for drug manufacturing.

Company
Samsung Biologics Co., Ltd.
Inspection date
May 11, 2018
Product type
biologics
Office
Food and Drug Administration
People
  • Virginia A. Carroll
  • Diane Raccasi (Microbiologist)
  • Michael R. Shanks (Investigator)
View Company Profile

ID · 61bb3e73-4ec2-4595-9016-297452948004

Violation Codes2
21 CFR 820.19821 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Samsung Biologics Co., Ltd.
  • 483 - 2025-05-27May 27, 2025
  • 483 - 2024-07-30July 30, 2024
  • EIR - 2024-07-30July 30, 2024
  • 483 - 2023-09-01September 1, 2023
  • 483 - 2023-02-20February 20, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Samsung Biologics Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.